Tonix Pharmaceuticals Q3 net loss widens

Tonix Pharmaceuticals Holding

10/11/2025 21:25

Overview

Tonix Q3 net loss widens to $32 mln

Company to launch Tonmya for fibromyalgia in November, first new treatment in 15 years

Tonix in-licenses TNX-4800 for Lyme disease, plans Phase 2/3 study in 2027

Outlook

Tonix expects cash reserves to fund operations into Q1 2027

Tonmya launch set for November 2025 with commercial infrastructure in place

Company plans to initiate TNX-4800 study during tick season in 2027

Result Drivers

Research and development expenses for the three months ended September 30, 2025 were $9.3 million, compared to $9.1 million for the same period in 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$32.01 mln
Q3 Operating Income
-$33.07 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $68.00, about 75% above its November 7 closing price of $17.00

Press Release: ID:nGNX6KCDn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)